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Introduction: GTI-2040, an antisense oligonucleotide, targets the
ribonucleotide reductase R2 subunit, critical for DNA synthesis.
This study determined the recommended phase II dose (RP2D) of
docetaxel plus GTI-2040, toxicity, and response rate in advanced
non-small cell lung cancer (NSCLC).
Patients and Methods: Advanced solid tumor patients, preferably
with platinum-treated NSCLC, performance status 0 to 2, no symp-
tomatic central nervous system metastases, adequate organ and bone
marrow function, and 1 prior chemotherapy regimen were treated
with escalating doses of GTI-2040 given by 14-day continuous
intravenous infusion (CVI) plus docetaxel every 21 days.
Results: Twenty-nine patients were treated, (24 NSCLC, 3 hor-
mone-refractory prostate cancer, 1 head and neck, and 1 small cell
lung cancer). GTI-2040 5 mg/kg as CVI for 14 days plus docetaxel
75 mg/m2 intravenously every 21days was determined as the RP2D.
Dose-limiting toxicity was not seen. Two patients at RP2D devel-
oped grade 4/5 febrile neutropenia. One prostate specific antigen
response was seen in phase I, but no objective tumor responses in the
NSCLC patients. Median time to progression was 3.4 months, 3.2
months in the NSCLC patients treated at RP2D.
Conclusions: Activity of the combination at RP2D, GTI-2040 5
mg/kg/d  14 days by CVI plus docetaxel 75 mg/m2 does not seem
superior to docetaxel alone in previously treated NSCLC.
Key Words: Antisense oligonucleotide, Lung cancer, Second-line,
Docetaxel, GTI-2040, Ribonucleotide reductase, R2 subunit.
(J Thorac Oncol. 2009;4: 1163–1169)
Lung cancer is the most common cause of cancer-relatedmortality in North American men and women, and annu-
ally, it causes more deaths than colorectal, breast, and pros-
tate cancer combined.1,2 The majority of patients are diag-
nosed with non-small cell lung cancer (NSCLC), and
approximately two-thirds of these present with locally ad-
vanced or metastatic disease. Median survival in advanced
NSCLC with systemic treatment is 8 to 10 months. After
failure of platinum-based chemotherapy, second-line treat-
ment with docetaxel in good performance status patients is
associated with a median survival improvement of 3 months
compared with best supportive care (7 versus 4 months), and
improved symptom control.3 However, the response rate of
second-line docetaxel, and agents like pemetrexed or erlo-
tinib, is only 6 to 10% in randomized trials.3–6 There is a clear
need for novel anticancer treatments to improve the outcome
of this disease.
Ribonucleotide reductase (RNR) is an enzyme that is
required in the reductive conversion of ribonucleotides to
deoxynucleotides during G1/S phase, a rate-limiting step
during DNA synthesis and repair. RNR is critical in cell
proliferation, and inactivation of the enzyme results in inhi-
bition of DNA synthesis, cell cycle arrest, and apoptosis.7,8
R2 can cooperate with ras, mitogen-activated protein kinase,
and other signaling pathways to enhance malignant potential.
R2 subunit overexpression seems to enhance oncogenic trans-
formation through v-src, A-raf, c-myc, v-fms, and v-fes.9 Its
expression may also increase drug-resistant properties of
tumor cells.10 Thus, RNR and its R2 subunit are attractive
targets for the anticancer drug development.
A GTI-2040 is an oligonucleotide antisense molecule
complementary to the mRNA encoding the R2 subunit of
RNR. It has been shown to inhibit growth of human lung and
other tumor cell lines in vitro in a dose-dependent fashion.11
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Its antitumor activity has been observed in various human
tumor types using severe combined immune deficiency or
nude mouse models, including lung cancer. Efficacy against
chemotherapy-resistant tumors has also been documented,
and it decreases the RNR R2 mRNA expression in cell lines,
with maximal inhibition at concentrations of 0.2 M, with
arrest in early G1/S cell cycle progression. In the phase I
study of single agent GTI-2040, the recommended phase II
dose (RP2D) was 5 mg/kg given by continuous infusion for
21 of 28 days.12 Disease stabilization was seen in 4 of 21
evaluable patients. Dose-limiting toxicities included hyperbi-
lirubinemia, transaminitis, and fatigue.
Docetaxel, a mitotic spindle poison, arrests cells in
G2/M phase, and it is an accepted standard for the second-
line treatment of advanced NSCLC. Although a phase I study
of single agent GTI-2040 in lung cancer has not been per-
formed, preclinical data suggest that it may have activity
against NSCLC, even in the setting of chemotherapy-resis-
tance, and that it may be synergistic with taxanes.11 Given the
differing mechanisms of action and toxicity profiles of do-
cetaxel and GTI-2040, we set out to examine the combination
using a phase I/II trial design. The study objectives were to
determine the RP2D of GTI-2040 in combination with do-
cetaxel in recurrent, metastatic, or advanced NSCLC; to
assess the objective tumor response rate of the combination in
pretreated NSCLC; to assess toxicity, stable disease rate, time
to disease progression, duration of response, and disease
stabilization of the combination; to investigate the pharma-
cokinetic parameters of GTI-2040 when given in combination
with docetaxel; to measure the baseline and posttreatment
levels of RNR activity in peripheral blood mononuclear cells;
and to explore the relationship between these potential cor-
relative endpoints and clinical outcome.
PATIENTS AND METHODS
This multicenter study was sponsored by the National
Cancer Institute (NCI) CTEP at three participating centers in
the Princess Margaret Hospital Phase II Consortium, (Prin-
cess Margaret Hospital/University Health Network, Toronto;
Juravinski Cancer Centre, Hamilton; Ottawa Hospital Re-
gional Cancer Centre, Ottawa). All participating institutions
received institutional research ethics board approval to con-
duct this study.
Patient Selection
For the phase I dose escalation portion of the study,
patients with histologic or cytologic confirmation of ad-
vanced solid malignancies were eligible to participate if they
had received up to one line of prior chemotherapy for ad-
vanced disease. For the phase II portion, eligible patients
were required to have recurrent, metastatic, or advanced
NSCLC, which was not amenable to curative or radical
treatment. They were required to have received one regimen,
(but not more than one), of prior chemotherapy for NSCLC.
Prior endothelial growth factor receptor inhibitor therapy,
endocrine therapy if appropriate (phase I), radiotherapy, and
surgery were permitted, but therapy must have been discon-
tinued at least 4 weeks before study entry. Prior docetaxel
therapy was not permitted. Patients were required to have
measurable disease, Eastern Cooperative Oncology Group
performance status 2, age 18 years, life expectancy 3
months, adequate hematopoietic (neutrophils 1.5  109/L,
platelets 100  109/L), hepatic and renal function, and
normal coagulation parameters. Patients with symptomatic or
progressive brain metastases, coagulopathy or therapeutic
anticoagulation, pre-existing neuropathy  NCI common
toxicity criteria grade 2, uncontrolled comorbid illness, con-
traindication or allergy to study treatment, HIV infection
receiving antiretroviral therapy, and pregnant or lactating
women were excluded. All patients provided written in-
formed consent to participate in the study according to
institutional guidelines.
Study Design
The GTI-2040 was administered as a continuous intra-
venous infusion (CVI) for 14 days starting on day 1 of each
cycle, followed by a 7-day break. This was amended from the
single-agent administration of 21 days by CVI followed by a
7-day break, to synchronize with standard 3-weekly do-
cetaxel administration, and to permit recovery from potential
overlapping toxicity. Docetaxel was administered intrave-
nously more than 1 hour on day 3 of cycle 1 (for pharmaco-
kinetic assessment), but on day 1 for subsequent cycles, with
standard dexamethasone premedication. Each cycle was de-
fined as 21 days, and dose escalation was based on safety data
from the first cycle of each cohort. The GTI-2040 was
supplied by the NCI CTEP, Division of Cancer Treatment
and Diagnosis, under a Clinical Trials Agreement with Lorus
Therapeutics Inc. (Toronto, Canada), and it was provided as
injection in glass vials containing 500 mg per vial. Docetaxel
is commercially available (Sanofi-Aventis Pharmaceuticals,
Inc.) and was sourced locally for this study. The planned dose
levels are shown in Table 1. Based on the GTI-2040 single
agent RP2D of 5 mg/kg/d,12 dose escalation to this maximum
dose was planned, in combination with standard dose do-
cetaxel 75 mg/m2 IV every 21 days.
For phase I, three patients were enrolled in each dose
level. If no dose-limiting toxicities were seen during the first
21-day cycle, three patients were enrolled at the next dose
level. If one patient experienced dose-limiting toxicity, an
additional three patients were to be enrolled at that dose level.
If two or more of six patients experienced dose-limiting
toxicity at any dose level, this would be considered the
TABLE 1. Dose Escalation Scheme
Dose
Level
GTI-2040
(mg/kg/d)
Docetaxel
(mg/m2) N Cycles DLT
Response
SD:PD:NE
Tumor
Type
1 3 60 3 14 0 2:1:0 3 NSC
2 5 60 4 7 0 2:1:1 3 NSC
1 SC
3 5 75 8 28 0 6:1:1 4 NSC
3 HRPC
1 H&N
DLT, dose-limiting toxicity; SD, stable disease; PD, progressive disease; NE, not
evaluable; NSC, non-small cell lung cancer; SC, small cell lung cancer; HRPC,
hormone refractory prostate cancer; H&N, head and neck cancer.
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maximum tolerated dose, and the dose level below would
be considered the RP2D. If no dose-limiting toxicity oc-
curred at the highest planned dose level, this would be
considered the RP2D.
Toxicities were graded according to the NCI common
toxicity criteria Version 2.0. To be considered dose-limiting,
toxicity had to occur during the first cycle of therapy and be
deemed at least possibly related to protocol treatment. Dose-
limiting toxicity was defined as following: grade 4 neutrope-
nia lasting more than 7 days; febrile neutropenia grade 3;
platelet count 25  109/L; thrombocytopenia resulting in
grade 2 hemorrhage; grade 3 infection with grade 3
neutropenia (1.0  109/L); grade 3 or 4 nonhematologic
toxicity except alopecia, nausea, emesis, diarrhea (unless
persistent despite preventive therapy); and inability to admin-
ister cycle 2 day 1 of combination within 2 weeks of com-
pleting previous cycle.
Patient Evaluation
All patients were required to have baseline history and
physical examination, performance status assessment, hema-
tology, biochemistry, coagulation, pregnancy test for women
of childbearing potential, and toxicity assessment within 7
days of starting treatment. Computed tomography of chest
and abdomen and other scans as necessary to document
disease were required within 28 days of starting therapy.
On treatment, patients underwent a history, physical
examination, and toxicity evaluation on day 1 of each cycle,
and weekly hematology and biochemistry during cycles 1 and
2, and on day 1 of subsequent cycles. Tumor imaging was
repeated every 6 weeks or sooner if clinically indicated.
All patients who completed at least one treatment cycle
were considered evaluable for response, and all patients who
received at least one dose of either GTI-2040 or docetaxel
were evaluated for toxicity. Tumor response and progression
were evaluated using the response evaluation criteria in solid
tumors.13 Complete or partial responses required confirma-
tion at least 4 weeks after initial documentation.
Dose Modifications
To receive full dose treatment on day 1, patients were
required to have an absolute neutrophil count 1.5  109/L,
platelet count100 109/L, bilirubin1.5 upper limit of
normal, aspartate transaminase/alanine aminotransferase
3.5  upper limit of normal, and nonhematologic toxicity
grade2. Treatment was withheld until any toxicity resolved
to grade 2 or less. Patients could be rechallenged on recovery
with reduced doses of therapy at the investigator’s discretion,
even after dose-limiting toxicity.
Treatment was discontinued in the case of serious or
unacceptable toxicity, or by patient request. Otherwise dura-
tion of therapy depended upon best response, with termina-
tion of treatment if progression, ongoing treatment if partial
response or stable disease, until evidence of progressive
disease, and if complete response was documented, a maxi-
mum of two cycles after confirmation of complete response.
Pharmacokinetics
Plasma samples for analysis of GTI-2040 were col-
lected during the first 3 cycles of therapy, at the following
time points: cycle 1 day 1 pretreatment at 2, 4, 8, 24, and 48
hours, (predocetaxel), day 15 (end of GTI-2040 infusion);
cycles 2 and 3, day 1 pretreatment (trough), day 15 (end
infusion), and cycle 4, day 1 pretreatment. These samples
were analyzed by high-performance liquid chromatograph
methodology developed by Zhang et al.,14 and plasma phar-
macokinetic variables calculated using noncompartmental
methods.
Pharmacodynamics
Peripheral blood mononuclear cells were collected at
baseline from fresh blood samples for patients treated at
RP2D and on day 3 of GTI-2040 single-agent therapy in
cycle 1. Total RNA was extracted and analyzed for mRNA
expression of RNR subunits (ribonucleotide reductase M1
(RRM1) and RRM2) and for housekeeping genes (HuPo and
TATA box binding protein) by real-time polymerase chain
reaction using the ABI 7900 HT Sequence Detection System
2.1, and these methods are further described in Juhasz et al.15
The RNA extracted from patient’s peripheral mononuclear
blood cells was quality assured by Agilent 2000 Bioanalyzer.
Only higher quality RNA samples were used for Real Time
polymerase chain reaction assay.
Statistical Methods
It was estimated that approximately 12 to 18 patients
would be required to complete the dose-escalation or phase I
portion of the study. The phase II portion of the study was
designed to declare the treatment active if the true objective
response rate was at least 20%, and to declare the treatment
inactive if the true objective response rate was at most 5%.
Thus, the design parameters were set to be P0  0.05, P1 
0.20,   0.10, and   0.10 and the optimal design of
Simon used.16 The treatment would be declared active if 4 or
more of 32 evaluable patients responded. Only NSCLC
patients treated at the RP2D in the dose-escalation phase
would be included in response assessment for the phase II
component of the study. The study was to be stopped early if
none of the first 18 patients assessed in phase II responded.
Descriptive statistics, such as the median, frequency,
and proportion, were used to summarize the cohort of patients
along with 95% confidence intervals (CIs) where possible.
The Kaplan-Meier method was used to estimate time to
progression and survival statistics. Overall survival was cal-
culated from the date the patient first received study treatment
until the date of death or last date the patient was known to
be alive. Time to progression was calculated from the date the
patient first received study treatment until the first date of
progression. Patients who were removed from treatment due
to an adverse event were censored in the time to progression
analysis on the date they came off of treatment.
RESULTS
Patient Characteristics
Twenty-nine patients entered the study, 15 in the dose
escalation phase including four NSCLC patients treated at
RP2D, (Table 1), and an additional 14 NSCLC patients
treated at RP2D in phase II. Two centers (Princess Margaret
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Hospital, Ottawa Hospital Regional Cancer Centre) partici-
pated in the dose escalation phase, and all three centers in the
phase II portion. Patient characteristics are listed in Table 2.
All NSCLC patients had received prior platinum-based ther-
apy, one as adjuvant treatment. Two NSCLC patients treated
at the RP2D had received prior therapy with endothelial
growth factor receptor tyrosine kinase inhibitors. All three
patients with prostate cancer in the dose escalation phase
were chemonaive.
Dose Escalation
Three patients were enrolled into the first dose level,
four into the second, and eight were treated at the RP2D in
the phase I portion of the study. No patient experienced
toxicity that was defined as dose limiting. The maximum
tolerated dose was not reached, and the RP2D was declared
as 5 mg/kg/d of GTI-2040 for 14 days by CVI plus docetaxel
75 mg/m2 intravenously on day 1 for every 21 days. One
patient in the second cohort experienced a malfunction of the
CVI pump and may have received treatment at an accelerated
rate. This patient was followed up for toxicity but not con-
sidered evaluable for response, and so a replacement patient
was enrolled to that cohort.
Treatment Received
A total of 93 cycles of therapy were delivered to the 29
patients on treatment, 49 in the dose escalation phase (15
patients), and 44 cycles to the additional 14 NSCLC patients
treated in the phase II portion. The median number of cycles
received was 2 (range 1–7).
Safety
Adverse events during the first cycle of the dose esca-
lation or phase I portion are listed in Table 3, with toxicity in
all cycles of the first 15 patients listed in Table 4. As the doses
of docetaxel and GTI-2040 increased during phase I, so did
the incidence of fatigue, and grade 3/4 leukopenia and neu-
tropenia. Significant toxicities beyond cycle 1 included two
patients treated at RP2D who experienced febrile neutrope-
nia. One patient developed Enterobacter bacteremia after
three cycles of therapy; another patient with hormone refrac-
tory prostate cancer and obstructive uropathy developed uro-
sepsis and expired in hospital after two cycles. Another
developed grade 3 anemia, two had grade 3 hyperglycemia
presumed secondary to dexamethasone premedication, and
three developed central catheter-related thromboses. Based
on the two patients with sepsis at RP2D beyond cycle 1, it
was felt that the dose of GTI-2040 combined with docetaxel
should not be escalated further to avoid incremental bone
marrow suppression. Of the 18 NSCLC patients treated at the
RP2D, 49 (89%) cycles were complicated by grade 3 or 4
toxicity (Table 5).
Efficacy
Twenty-six of twenty-nine patients were evaluated for
response. One patient in the dose finding portion of the study
(dose level 2) was not evaluated because of deviation from
treatment administration (pump malfunction). One patient
with prostate cancer treated at dose level 3 developed febrile
neutropenia during cycle 2 was removed from study and was
not evaluated for response. Another patient progressed clin-
ically after cycle 1 and stopped therapy. No objective tumor
responses were seen in either portion of the study. One
prostate cancer patient treated at RP2D had a PSA response,
and four others treated in the dose escalation phase had minor
tumor shrinkage that did not meet partial response criteria
by RECIST.
Twelve of eighteen NSCLC treated at RP2D had stable
disease as their best response after cycle 2. Three had minor
tumor regression that did not meet response criteria by
RECIST (11–14% decrease).
The median time to progression was 3.4 months (95%
CI: 2.6 months–not reached, Figure 1) in both portions of the
trial. For NSCLC patients treated in the phase II, median time
to progression was 3.2 months, (95% CI: 1.5 months–not
TABLE 2. Patient Characteristics
Dose Escalation Phase Phase II in NSCLCa
N 15 18
Median age (range) 61 (27–75) 53 (27–75)
Gender M:F 10:5 9:9
Performance status 0:1:2 6:9:0 6:9:3
Prior chemotherapy 12 18
Prior radiation 8 15
Tumor type
NSCLC 10 18
Prostate 3
SCLC 1
Head and neck 1
a NSCLC patients treated at recommended phase II dose, including 4 patients from
dose escalation phase.
N, number of patients; M, male; F, female; NSCLC, non-small cell lung cancer;
SCLC, small cell lung cancer.
TABLE 3. Phase I Cycle 1 Toxicity
GTI-2040
(mg/kg/d)
Docetaxel
(mg/m2)
Non-Hematologic Toxicity Laboratory, Hematologic Toxicity
Fatigue Edema Alopecia GI Glucose WBC ANC HGB
2 3 4 2 3 4 2 3 4 2 3 4 2 3 4 2 3 4 2 3 4 2 3 4
3 60 1 2 2 1 1 1
5 60 2 1 1 1 1 1 2
5 75 3 1 4 1 1 2
GI, gastrointestinal; WBC, white blood count; ANC, absolute neutrophil count; HGB, hemoglobin.
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reached; Figure 2). Thirteen of the entire sample discontinued
therapy for reasons of disease progression, five for reasons of
toxicity, four stopped at patient request, six at investigator
discretion, and one was withdrawn for incorrect treatment
administration. Five patients completed six cycles of treat-
ment, two at dose level 1, and three at dose level 3, including
one patient with prostate cancer.
All patients have died. Median survival for the entire
cohort was 8.6 months, (95% CI: 6.7–10.0 months) and 7.9
months (95% CI: 3.2–10.0 months) for NSCLC patients
treated at RP2D. Survival at 6 months was 61.1% (95% CI:
42.3–88.3%), and 11.1% (95% CI: 3.0–41.0%) at 1 year for
those treated at RP2D (Figure 2).
Pharmacokinetics
The average steady-state concentration of GTI-2040
during cycle 1 was 0.5  0.2 g/ml (range: 0.2–1.0 g/ml)
for patients at 3mg/kg dose level, and 1.6  0.9 g/ml
(range: 0.2–4.7 g/ml) for patients at 5 mg/kg dose level,
(Figure 3). Given preclinical evidence of decreases in RRM2
subunit mRNA expression in human tumor cell lines at
concentrations of 1.2 g/ml, the steady-state concentration of
GTI-2040 at the 5 mg/kg dose level seems to be sufficient,
although intratumoral concentrations have not been assayed.
There was no clear evidence that GTI-2040 levels were
influenced by docetaxel administration.
TABLE 4. Phase I Adverse Events, All Cycles
Toxicity
No. of
Patients
(n  15)
No. of
Cycles
(n  49)
No. of
Cycles
> Grade 3
(n  49)
No. of
Patients
Grade 5
Fatigue 15 (100%) 45 (92%) 1 (2%)
Edema 3 (20%) 6 (12%) 0
Alopecia 9 (60%) 29 (59%) 0
Hyperglycemia 13 (87%) 37 (76%) 8 (16%)
Nausea 7 (47%) 10 (20%) 0
WBC 14 (93%) 34 (69%) 15 (31%)
ANC 12 (80%) 28 (57%) 18 (37%)
Hemoglobin 14 (93%) 43 (88%) 1 (2%)
Platelet 5 (33%) 8 (16%) 1 (2%)
Infection with
neutropenia
3 (20%) 3 (6%) 3 (6%) 1 (7%)
Thrombosis 3 (20%) 4 (8%) 3 (6%)
WBC, white blood cell; ANC, absolute neutrophil count.
TABLE 5. Selected Adverse Events, in Patients Treated at
RP2D (N  18)
Toxicity
No. of
Patients
(n  18)
No. of
Cycles
(n  55)
No. of
Cycles
> Grade 3
(n  55)
No. of
Patients
> Grade 3
(n  18)
Fatigue 15 (83%) 47 (85%) 4 (7%) 4 (22%)
Nausea 12 (67%) 25 (45%) 0 0
Dyspnea 10 (56%) 28 (51%) 5 (9%) 4 (22%)
Alopecia 9 (50%) 28 (51%) 0 0
Thrombosis 5 (28%) 14 (25%) 14 (25%) 5 (28%)
Edema 3 (17%) 6 (11%) 0 0
Infection without
neutropenia
3 (17%) 5 (9%) 1 (2%) 1 (6%)
Infection with
neutropenia
1 (6%) 1 (2%) 1 (2%) 1 (6%)
Hemoglobin 17 (94%) 49 (89%) 2 (4%) 2 (11%)
WBC 16 (89%) 43 (78%) 24 (44%) 10 (56%)
ANC 12 (67%) 34 (62%) 26 (47%) 12 (67%)
Platelet 8 (44%) 14 (25%) 1 (2%) 1 (6%)
Transfusion 1 (6%) 1 (2%) 1 (2%) 1 (6%)
Hyperglycemia 15 (83%) 36 (65%) 7 (13%) 3 (17%)
WBC, white blood cell; ANC, absolute neutrophil count; RP2D, recommended
phase II dose.
FIGURE 1. Time to progression, non-small cell lung cancer
(NSCLC) patients at RP2D (n  18). RP2D, recommended
phase 2 dose.
FIGURE 2. Overall survival, non-small cell lung cancer
(NSCLC) patients treated at RP2D. RP2D, recommended
phase 2 dose.
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Pharmacodynamics
Peripheral blood mononuclear samples were collected
from eight patients treated at RP2D, 7 with NSCLC, one with
hormone refractory prostate cancer. There did not seem to be
any relationship between RRM2 levels and duration of ther-
apy, response, or toxicity in these eight patients.
DISCUSSION
The combination of GTI-2040 and docetaxel resulted in
manageable toxicity, and it is unlikely that the dose of
GTI-2040 could be escalated further without severe overlap-
ping toxicities with docetaxel. The combination did not yield
objective responses in pretreated NSCLC patients, although
one prostate cancer patient had a PSA response. The time to
progression of 3.2 months in the NSCLC patient cohort is
consistent with the published literature in the setting of
second-line single-agent docetaxel. The lack of objective
responses is also consistent with docetaxel therapy, with an
historical response rate of only 6 to 9% in the randomized
trials of second-line treatment in NSCLC.3–6 The pharmaco-
kinetic data suggest that although plasma levels of GTI-2040
achieved in this study would be expected to suppress RRM2
subunit activity, there is evidence of significant interpatient
variability. Thus, higher doses of GTI-2040 may be required
to ensure sufficient levels in all patients. Despite the small
number of pharmacodynamic samples available, only one of
eight patients demonstrated evidence of reduced RRM2 ac-
tivity, again raising the question of insufficient dosing of
GTI-2040.
It may be possible to further escalate dose by shorten-
ing the duration of GTI-2040 exposure, for example to 5 or 7
days by continuous infusion. It has been reported that RRM2
down-regulation occurs within 24 hours of GTI-2040 admin-
istration and is sustained over at least 7 days with continuous
infusion.15,17 Marcucci et al. have been able to escalate to 7
mg/kg/d, in combination with cytarabine, over a shorter
period in elderly patients with acute myeloid leukemia with-
out significant additional toxicity.18 Achieving significant
levels of R2 down-regulation over a 6-day infusion may
render longer infusion periods unnecessary. Alternately, com-
bination with less toxic agents like pemetrexed or erlotinib
could permit further dose escalation of GTI-2040.5,6
Another question is whether the sequence of agents
may impact on efficacy. Although initial preclinical studies
suggested synergy with concurrent administration of GTI-
2040 and taxanes, hence the concurrent administration used
in the clinical trial, more recent studies suggest that the
potential for chemosensitization by RRM2 down-regulation
persists for up to 72 hours after the end of GTI-2040 treat-
ment. Additional preclinical studies suggest that sequential
rather than concurrent administration of the two agents may
yield superadditive effects.19 However, this hypothesis would
need to be tested clinically.
Antisense technology in drug development has the
advantage of high specificity and selective gene inhibition,
with the potential to maximize target inhibition while mini-
mizing toxicity and off-target effects. However, the clinical
development of antisense oligonucleotides has been limited
by their short plasma half life, poor stability in physiologic
fluids, and limited intracellular uptake. Although prolonged
infusion may address the short half life of these compounds,
these are inconvenient and may not ensure adequate tumor
delivery of drug for target inhibition. Other antisense oligo-
nucleotides have been evaluated in lung cancer, including
aprinocarsen and oblimersen, antisense to protein kinase
C-alpha and bcl-2, respectively.20–22 Despite promising pre-
clinical data and minimal toxicity when added to chemo-
therapy, neither has yet been shown to improve lung
cancer outcomes.
Finally, it may be that the RRM2 subunit is not an
important target in NSCLC. Although critical for DNA syn-
thesis, it is overexpressed in cancer cells and seems to
facilitate signal transduction and oncogenic transformation
through several pathways, it may not be a critical target in
NSCLC. Other RNR inhibitors have met with variable
success, such as hydroxyurea, which has minimal activity
FIGURE 3. Steady state concentrations
GTI-2040.10
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in lung cancer. By contrast, gemcitabine, which primarily
inhibits function of the R1 subunit, has impressive single
agent activity, and it is used as a standard agent in the
first-line setting.
GTI-2040 combined with docetaxel at the tested dose
and schedule demonstrates evidence of disease stabilization
with some minor tumor responses. However, the addition of
GTI-2040 does not show significant incremental benefit over
docetaxel alone in pretreated NSCLC, though the numbers
treated in this study are small. Further testing of this inter-
esting compound should focus on differential sequencing,
shorter duration of higher dose treatment, or an alternate
agent for combination strategies.
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